IMS Health

IMS Health was a United States-based healthcare information, services, and technology company whose activities formed a major part of the business now operating under the IQVIA name. Founded in 1954 as Intercontinental Marketing Statistics, the company built a global information infrastructure for pharmaceutical and healthcare markets. Its datasets covered pharmaceutical sales, prescription activity, medical claims, electronic medical records, healthcare facilities, and other de-identified or aggregated information. These resources were used by pharmaceutical manufacturers, biotechnology companies, healthcare providers, payers, and investors to understand treatment markets, evaluate commercial performance, identify patient and physician populations, and plan product portfolios. The company became particularly well known for physician prescribing and pharmaceutical market data in the United States. Its business model combined data collection with syndicated market reports, forecasting, consulting, analytics, software, and technology-enabled services. Rather than operating primarily as a drug developer or healthcare provider, IMS Health served as an information and decision-support intermediary for the life-sciences industry. Its offerings supported launch planning, sales-force effectiveness, market measurement, health economics and outcomes research, pricing, reimbursement analysis, and commercial strategy. IMS Health expanded through a long series of acquisitions. These transactions broadened its capabilities from traditional market statistics into patient-centric claims data, healthcare facility information, analytics, software-as-a-service products, customer relationship management, social-media analysis, clinical-trial planning, payer services, and pharmaceutical transaction intelligence. The company also developed a broad international footprint, including operations and acquisitions in Europe, Canada, China, India, Russia, and other markets. The company experienced several changes in ownership and corporate structure. Its former parent, Cognizant Corporation, separated IMS Health and Nielsen Media Research in 1998. IMS Health subsequently divested its stake in Cognizant Technology Solutions in 2003, leaving the two companies independent. In 2010, a consortium consisting of TPG Capital, the Canada Pension Plan Investment Board, and Leonard Green & Partners took IMS Health private. The company returned to the public markets in 2014, listing on the New York Stock Exchange under the symbol IMS. In 2016, IMS Health merged with Quintiles, a major contract research and clinical development services company. The combined organization was initially named QuintilesIMS, bringing together IMS Health's healthcare data and commercial capabilities with Quintiles' clinical research and contract development operations. On November 6, 2017, the company adopted the name IQVIA. Accordingly, IMS Health is best understood as the historical corporate entity and principal predecessor represented by the authoritative Wikipedia subject, while IQVIA is the continuing successor brand and public company. The historical IMS Health business ended as a standalone brand after the Quintiles combination and subsequent rebranding.

IMS Health originated in 1954 as Intercontinental Marketing Statistics, a name reflected in the initials IMS. Founded by Bill Frohlich and David Dubow, the company developed a business around collecting, organizing, and interpreting information about pharmaceutical markets. Its data became especially significant in the United States, where IMS Health was recognized as the largest supplier of physician prescribing information. Over time, the company expanded beyond prescription statistics into pharmaceutical sales measurement, medical claims, electronic medical records, healthcare facility profiles, and other forms of de-identified or aggregated healthcare information. IMS Health's customers used its information to estimate market size, forecast demand, compare product performance, identify treatment and prescriber patterns, plan product launches, and allocate commercial resources. The company combined proprietary datasets with consulting and analytical services, producing syndicated reports as well as client-specific studies. Its scope gradually broadened to include health economics and outcomes research, payer services, commercial effectiveness, customer relationship management, clinical-trial planning, and software-supported analytics. Corporate restructuring marked several important stages in the company's development. In 1998, the former parent Cognizant Corporation separated IMS Health from Nielsen Media Research. IMS Health retained a connection to Cognizant Technology Solutions for a period, but sold its entire stake in 2003, making the two organizations independent. The company pursued extensive acquisition activity during the 2000s and 2010s. Acquisitions added pharmaceutical consulting, forecasting, patient-level claims, healthcare facility data, international market intelligence, clinical-trial enrollment tools, payer analytics, software-as-a-service products, customer relationship management, social-media monitoring, and pharmaceutical transaction information. In February 2010, IMS Health was acquired by TPG Capital, the Canada Pension Plan Investment Board, and Leonard Green & Partners. It later returned to the public markets on April 4, 2014, trading on the New York Stock Exchange under the symbol IMS. The company continued to enlarge its software, diagnostics-market, data-management, and consulting portfolio through additional acquisitions, including purchases connected with Cegedim's CRM and strategic data activities, Dataline Software, and Boston Biomedical Consultants. A decisive transformation came in 2016, when IMS Health merged with Quintiles. The transaction combined a healthcare information and commercial-services business with a large clinical research organization. The merged company was named QuintilesIMS and had a reported ownership split in which former IMS Health shareholders held the larger portion. On November 6, 2017, QuintilesIMS adopted the name IQVIA. This rebranding marked the end of IMS Health as a standalone corporate identity, while preserving its data, analytics, technology, and commercial-services activities within IQVIA. IMS Health's data practices also generated controversy. Critics and litigants questioned the privacy implications and commercial use of prescribing information, even when the information was anonymized or aggregated. The company was involved in IMS Health v. Ayotte and Sorrell v. IMS Health Inc. The latter reached the United States Supreme Court and concerned restrictions on the use of physician-identifying prescription information for pharmaceutical marketing. The Court ruled in favor of IMS Health on free-speech grounds. These disputes helped make IMS Health an important case study in the tension between data-driven healthcare commerce, physician privacy, public-health information, and commercial speech.

1. 2017Rebranded as IQVIA

   QuintilesIMS adopted the IQVIA name on November 6.

   Source
2. 2016Merger with Quintiles

   The merger created the combined company QuintilesIMS.

   Source
3. 2014Return to public trading

   IMS Health listed on the New York Stock Exchange under the ticker IMS.

   Source
4. 2010IMS Health taken private

   A consortium led by TPG Capital acquired the company.

   Source
5. 2003IMS Health and Cognizant became independent

   IMS Health sold its remaining 56 percent stake in Cognizant Technology Solutions.

   Source
6. 1998Cognizant Corporation restructured

   Cognizant Corporation separated IMS Health and Nielsen Media Research into distinct businesses.

   Source
7. 1954Intercontinental Marketing Statistics founded

   The company that later became IMS Health was established by Bill Frohlich and David Dubow.

   Source

Premium, data-intensive healthcare intelligence and life-sciences services provider

• Pharmaceutical market intelligenceHealthcare data

  IMS Health's core business measured pharmaceutical sales, prescriptions, and market activity across countries and therapeutic areas. These datasets supported market sizing, competitive analysis, forecasting, sales-force planning, product-launch preparation, and evaluation of commercial performance. The information was delivered through syndicated reports, databases, and analytical services.

• Patient-centric claims and real-world dataReal-world evidence2005

  Through its own data assets and acquisitions such as PharMetrics and SDI Health, IMS Health developed patient-level and claims-based capabilities. These resources enabled analysis of treatment pathways, utilization, outcomes, payer behavior, and patient populations, subject to applicable privacy and data-use constraints.

• Clinical trial planning and enrollment technologyClinical research technology2012

  Acquisitions including DecisionView and TTC expanded IMS Health's ability to help life-sciences organizations plan clinical-trial enrollment, monitor recruitment, benchmark trial costs, and negotiate development-related expenditures.

• Commercial software and healthcare CRMHealthcare software2013

  IMS Health broadened its software portfolio through acquisitions involving sales-performance management, multichannel customer relationship management, relationship marketing, and social-media analytics. These tools supported interactions among pharmaceutical companies, physicians, payers, and other healthcare stakeholders.

• Health economics and outcomes researchHealthcare consulting2007

  The company provided analytical and consulting capabilities for assessing treatment value, healthcare utilization, outcomes, and reimbursement considerations. These services helped life-sciences clients connect clinical evidence with payer, policy, and market-access decisions.

• 2017Adopt the IQVIA identityStrategy

  Following the IMS Health–Quintiles combination, the company needed a unified identity representing data, technology, analytics, and clinical research.

  What changed. QuintilesIMS changed its name to IQVIA on November 6, 2017.

  Aftermath. IMS Health ceased to operate as the standalone corporate brand represented by the historical Wikipedia article.

  Source
• 2016Merge with QuintilesM&A

  IMS Health sought to combine healthcare data, analytics, and commercial services with Quintiles' clinical research and contract development capabilities.

  What changed. The companies merged and created QuintilesIMS.

  Aftermath. The combined organization was renamed IQVIA in 2017 and continued under the IQV ticker.

  Reported combined company value. $17.6 billion (2016)

  Source
• 2014Return to public marketsStrategy

  After several years under private ownership, IMS Health pursued a new public listing.

  What changed. The company listed on the New York Stock Exchange under the symbol IMS.

  Aftermath. The listing restored IMS Health's status as a public company until its combination with Quintiles.

  Source
• 2010Accept a take-private transactionM&A

  IMS Health was acquired after operating as a public company and entered private ownership under a consortium of financial sponsors.

  What changed. TPG Capital, the Canada Pension Plan Investment Board, and Leonard Green & Partners took the company private.

  Aftermath. IMS Health later returned to public trading in 2014.

  Source

• Disputes over prescribing-data privacy and commercial speechControversy

  IMS Health's collection and use of prescribing information generated privacy and free-speech controversy. In Sorrell v. IMS Health Inc., the United States Supreme Court considered a Vermont restriction on the sale, disclosure, and use of physician-identifying prescription information for pharmaceutical marketing. The Court ruled in favor of IMS Health, holding that the restriction violated the First Amendment. The company was also involved in IMS Health v. Ayotte.

  Source

• 2017The combined company adopted the IQVIA name

  QuintilesIMS changed its corporate name to IQVIA, completing the transition from the historical IMS Health identity.

  Leadership changeOther
  Source
• 2017Combined company renamed IQVIA

  QuintilesIMS adopted the IQVIA name, completing the post-merger rebranding of the former IMS Health business.

  M&AOther
  Source
• 2016IMS Health and Quintiles announced a merger

  The companies agreed to combine IMS Health's healthcare information and commercial services with Quintiles' clinical research capabilities.

  M&A
  Source
• 2016IMS Health and Quintiles announce merger

  IMS Health announced a combination with Quintiles that created QuintilesIMS, integrating healthcare data and analytics with clinical-development and commercialization services.

  M&ALeadership change
  Source
• 2014IMS Health returned to the public market

  IMS Health completed a public listing on the New York Stock Exchange under the symbol IMS.

  Other
  Source
• 2014IMS Health returns to the public market

  IMS Health began trading on the New York Stock Exchange after completing its return to public ownership.

  Other
  Source
• 2011Sorrell v. IMS Health reaches the United States Supreme Court

  The Supreme Court considered Vermont restrictions on the sale, disclosure, and use of prescriber-identifying information for pharmaceutical marketing. The Court ruled in favor of IMS Health, treating the restriction as an unconstitutional burden on protected speech.

  LawsuitRegulation
  Source
• 2010IMS Health taken private by a financial sponsor consortium

  TPG Capital, the Canada Pension Plan Investment Board, and Leonard Green & Partners acquired IMS Health and removed it from public ownership.

  M&A
  Source
• 2010IMS Health taken private by investor consortium

  TPG Capital, CPP Investment Board, and Leonard Green & Partners completed a transaction taking IMS Health private.

  M&AOther
  Source
• IMS Health v. Ayotte

  A legal dispute involving IMS Health concerned the company’s ability to use and communicate information derived from prescription data and raised free-speech issues.

  LawsuitRegulation
  Source

1. IMS Health